section name header

Pronunciation

ta-DA-la-fil

Classifications

Therapeutic Classification:erectile dysfunction agents, vasodilators

Pharmacologic Classification: phosphodiesterase type 5 inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Extensive tissue distribution; penetrates semen.

Protein Binding: 94%.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP3A4 isoenzyme system; metabolites are excreted in feces (61%) and urine (36%).

Half-life: 17.5 hr.

Time/Action Profile

(vasodilation, improved erectile function)

ROUTEONSETPEAKDURATION
POrapid0.5–6 hr36

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, peripheral edema.

Derm: flushing.

EENT: hearing loss, nasal congestion, vision loss.

GI: diarrhea, dyspepsia.

GU: fertility, priapism.

MS: back pain, limb pain, myalgia.

Neuro: headache.

Interactions

Drug-Drug:

Route/Dosage

Cialis (for ED)

Renal Impairment

Hepatic Impairment

Cialis (for BPH or ED/BPH)

Renal Impairment

Hepatic Impairment

Adcirca, Alyq, and Tadliq (for PAH)

Renal Impairment

Hepatic Impairment

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Adcirca, Alyq, Cialis, Tadliq

Pill Image

tadalafil_195_8685.jpg